Recursion founder & Chair Chris Gibson will not stand for re-election; to become advisor

RECURSION PHARMACEUTICALS, INC.

Chris Gibson, Ph.D., founder and Chair, will not seek re-election at 2026 Annual Meeting (June 2026).
He will continue as Chair until term ends, then serve as strategic advisor to the company.
Gibson stated decision not due to any disagreement with Recursion on operations, policies, or practices.
CEO Najat Khan thanked Gibson, emphasizing continuity, pipeline progress, and long-term value creation.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Christopher Gibson

Chair of the Board of Directors

RXRX · RECURSION PHARMACEUTICALS, INC.

Effective: 2026-06-01
Filed: April 30, 2026, 7:59 PM ET

On April 28, 2026, Christopher Gibson, Ph.D., Chair of the Board of Directors (the “Board”) of Recursion Pharmaceuticals, Inc. (the “Company”) and a member of the Research and Development Committee, Technology Committee, and the Corporate Social Responsibility Committee of the Board, informed the Company that he will not stand for re-election to the Board as a Class II Director at the 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Christopher Gibson departed as Chair of the Board of Directors at RECURSION PHARMACEUTICALS, INC..

Action: will not stand for re-election
Role: Chair of the Board of Directors

Exact text from the filing

On April 28, 2026, Christopher Gibson, Ph.D., Chair of the Board of Directors (the “Board”) of Recursion Pharmaceuticals, Inc. (the “Company”) and a member of the Research and Development Committee, Technology Committee, and the Corporate Social Responsibility Committee of the Board, informed the Company that he will not stand for re-election to the Board as a Class II Director at the 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”).

View on SEC.gov

RECURSION PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001601830-26-000064

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.